CARA:NSD-Cara Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 15.31

Change

+0.06 (+0.39)%

Market Cap

USD 0.77B

Volume

0.72M

Avg Analyst Target

USD 25.75 (+68.19%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut. Address: 4 Stamford Plaza, Stamford, CT, United States, 06902

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-6.72 (-1.56%)

USD173.59B 50.81 42.25
BNTX BioNTech SE

-20.17 (-5.62%)

USD82.22B 18.72 15.10
REGN Regeneron Pharmaceuticals Inc

-10.99 (-1.69%)

USD69.72B 11.77 9.06
VRTX Vertex Pharmaceuticals Incorpo..

-2.63 (-1.40%)

USD48.85B 24.83 16.63
BGNE BeiGene Ltd

-4.64 (-1.15%)

USD42.80B N/A N/A
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

+2.85 (+1.82%)

USD28.42B 48.74 39.11
GMAB Genmab A/S

-0.18 (-0.42%)

USD28.19B 71.63 8.17
RPRX Royalty Pharma plc

-1.67 (-4.34%)

USD23.38B 31.17 12.50
ALNY Alnylam Pharmaceuticals Inc

-6.88 (-3.61%)

USD21.80B N/A N/A

ETFs Containing CARA

Symbol Name Weight Mer Price(Change) Market Cap
MJX ETFMG Alternative Harvest.. 0.00 % 0.00 %

-0.01 (-5.71%)

N/A
CBDX:LSE The Medical Cannabis and .. 0.00 % 0.80 %

-0.15 (-1.27%)

N/A
CBSX:XETRA Hanetf ICAV - Hanetf Alte.. 0.00 % 0.80 %

-0.15 (-1.51%)

USD0.04B
BLUM:F Rize Ucits ICAV - Rize Me.. 0.00 % 0.65 %

N/A

N/A
CBSX:F Hanetf ICAV - Hanetf Alte.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.19% 65% D 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.19% 65% D 42% F
Trailing 12 Months  
Capital Gain 8.20% 59% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.20% 59% F 31% F
Trailing 5 Years  
Capital Gain 103.86% 73% C 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 103.86% 73% C 70% C-
Average Annual (5 Year Horizon)  
Capital Gain 9.56% 46% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.56% 46% F 47% F
Risk Return Profile  
Volatility (Standard Deviation) 32.82% 83% B 56% F
Risk Adjusted Return 29.14% 55% F 43% F
Market Capitalization 0.77B 68% D+ 61% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 90.06 11% F 12% F
Price/Book Ratio 3.75 48% F 38% F
Price / Cash Flow Ratio -139.76 97% A+ 92% A-
EV/EBITDA 86.73 8% F 10% F
Management Effectiveness  
Return on Equity 4.85% 93% A 59% F
Return on Invested Capital 2.79% 87% B+ 60% D-
Return on Assets 2.19% 93% A 65% D
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.16 81% B- 75% C
Short Percent 8.62% 30% F 20% F
Beta 1.07 66% D 55% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.